½ÃÀ庸°í¼­
»óǰÄÚµå
1594358

±¸³»¿° Ä¡·áÁ¦ ½ÃÀå : ¾à¹° Á¾·ùº°, Á¦Çüº°, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Mouth Ulcers Treatment Market by Drug Class (Analgesics, Antihistamine, Antimicrobial), Formulation (Gels & Ointments, Mouthwash, Sprays), End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 193 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

±¸³»¿° Ä¡·áÁ¦ ½ÃÀåÀº 2023³â 12¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ°í 2024³â¿¡´Â 13¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, CAGR 5.26%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 17¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±¸³»¿° Ä¡·áÁ¦ ½ÃÀå¿¡´Â ±¸°­³» ¹ß»ýÇÏ´Â °íÅ뽺·¯¿î ±Ë¾çÀÎ ±¸³»¿°(¾ÆÇÁŸ¼º ±Ë¾ç)ÀÇ Áõ»óÀ» ¿ÏÈ­Çϰí Ä¡À¯¸¦ ÃËÁøÇÏ´Â Á¦Ç° ¹× Ä¡·á¹ýÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Ä¡·áÀÇ Çʿ伺Àº ½ºÆ®·¹½º, ¿µ¾ç ºÎÁ·, ƯÁ¤ °Ç°­ »óÅ µîÀÇ ¿øÀÎÀ¸·Î ÀÎÇØ Àα¸ÀÇ »ó´ç¼ö°¡ ¾Î°í ÀÖ´Â ±¸³»¿°ÀÇ À¯ÇàÀ¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ±¸³»¿° Ä¡·á¿¡´Â Áï°¢ÀûÀÎ ¿ÏÈ­ ¹× Ä¡À¯¸¦ ÃËÁøÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ½ÃÆÇ¿ë Á©, Å©¸², ¼¼Á¤Á¦, ó¹æ¾à µîÀÌ Æ÷ÇԵ˴ϴÙ. ÃÖÁ¾ »ç¿ë ºÐ¾ß´Â º´¿ø, Ä¡°ú ¹× ÀçÅà ġ·á ÇöÀåÀ» Æ÷ÇÔÇϸç, Àü¹® Ä¡°ú Ä¡·á¿¡¼­ ÀÚ°¡ °ü¸® ¼Ö·ç¼Ç¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ¼ÒºñÀÚÃþÀ» ¹Ý¿µÇÕ´Ï´Ù. ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â ±¸°­ °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Á¦¾à Á¦Á¦ÀÇ ¹ßÀü, Áï°¢ÀûÀÎ ¿ÏÈ­ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. À¯±â³ó Á¦Ç°¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ õ¿¬ ¼ÒÀç ¹× Çãºê ±â¹Ý Ä¡·á¹ý °³¹ß¿¡ »õ·Î¿î ºñÁî´Ï½º ±âȸ°¡ »ý°Ü³ª°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µµ½ÃÈ­ÀÇ ÁøÀü°ú ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­´Â ¿¹¹æÀÇÇп¡ ´ëÇÑ °ü½ÉÀ» ºÒ·¯ÀÏÀ¸Å°°í ÀÖÀ¸¸ç, ±â¾÷µéÀº ¿¹¹æÀÇÇÐ ¼Ö·ç¼ÇÀ» Çõ½ÅÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀå ¼ºÀå¿¡´Â Á¦Ç° È¿´É¿¡ ´ëÇÑ ¿ì·Á, ÀáÀçÀû ºÎÀÛ¿ë, ½ÅÈï ½ÃÀå¿¡¼­ÀÇ °¡°Ý ¾Ð·Â µîÀÇ ¿äÀÎÀÌ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °³¹ßµµ»ó±¹¿¡¼­ÀÇ ³·Àº ÀÎÁöµµµµ Á¦¾à ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¾à¹° ¼­¹æÈ­¸¦ À§ÇÑ ³ª³ë±â¼úÀÇ Àû¿ë°ú Ç¥Àû Ä¡·á¸¦ À§ÇÑ ¹ÙÀÌ¿À±â¼úÀÇ È°¿ë¿¡ ÀÖ¾î Çõ½ÅÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¿¹Ãø ¸ðµ¨¸µ°ú °³ÀÎÈ­µÈ Ä¡·á °èȹÀ» À§ÇÑ ¿¬±¸¿¡ ÀΰøÁö´ÉÀ» ´õ ¸¹ÀÌ ÅëÇÕÇÏ´Â °ÍÀº ºñÁî´Ï½º ¼ºÀåÀÇ »õ·Î¿î ÁöÆòÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ°í ¾à¹°Àü´ÞÀÇ È¿°ú¸¦ ±Ø´ëÈ­ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸´Â Ä¡·á °á°ú¸¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù. ±âÁ¸ Á¦¾à»ç¿Í ½Å±Ô ÁøÀÔÀÚµéÀÌ ¹ÙÀÌ¿À ģȭÀûÀÌ°í ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» ã±â À§ÇÑ ½ÃÀå °æÀïÀº °è¼ÓµÇ°í ÀÖÀ¸¸ç, ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ À¯ÁöÇÏ°í »õ·Î¿î ±âȸ¸¦ Ȱ¿ëÇϱâ À§Çؼ­´Â Àü·«Àû Á¦ÈÞ¿Í Áö¼ÓÀûÀÎ Çõ½ÅÀÌ Áß¿äÇÏ´Ù´Â Á¡ÀÌ °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ[2023] 12¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ[2024] 13¾ï ´Þ·¯
¿¹Ãø ¿¬µµ[2030] 17¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 5.26%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ±¸³»¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù

±¸³»¿° Ä¡·áÁ¦ ½ÃÀåÀº ¼ö¿ä¿Í °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ÃËÁø¿äÀÎ
    • Àü ¼¼°è Àα¸ÀÇ ³ôÀº ±¸³»¿° À¯º´·ü
    • ±¸³»¿° Ä¡·á¿ë ½ÃÆÇ Á¦Ç°ÀÇ °¡¿ë¼º
    • ȯÀÚ Áß½ÉÀÇ ±¸°­ ±Ë¾ç Ä¡·á °èȹÀÇ Á߿伺 Áõ´ë
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
    • ±¸³»¿°¿¡ ´ëÇÑ ±âÁ¸ Ä¡·á¹ýÀÇ È¿°ú°¡ Á¦ÇÑÀûÀÓ.
  • ½ÃÀå ±âȸ
    • º¸´Ù È¿°úÀûÀÎ »õ·Î¿î ±¸³»¿° Ä¡·á¹ý ¼Ò°³
    • ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ±¸°­ À§»ý¿¡ ´ëÇÑ °ü½É Áõ´ë
  • ½ÃÀå °úÁ¦
    • ±¸³»¿°°ú °ü·ÃµÈ ƯÁ¤ ºÎÀÛ¿ë

Porter's Five Forces : ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå °ø·«À» À§ÇÑ Àü·«Àû µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï »óȲÀ» ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ±¸³»¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ±¸³»¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå¿¡¼­ÀÇ °æÀï »óȲ ÆÄ¾Ç

±¸³»¿° Ä¡·áÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

±¸³»¿° Ä¡·áÁ¦ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

±¸³»¿° Ä¡·áÁ¦ ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ µµÀü°úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï »óȲÀ» öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ÇâÈÄ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº ¾îµðÀΰ¡?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õÀÇ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå : ¾à¹° Á¾·ùº°

  • ÁøÅëÁ¦
  • Ç×È÷½ºÅ¸¹ÎÁ¦
  • Ç×±Õ¼º
  • ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å

Á¦7Àå ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå ó¹æº°

  • Á©°ú ¿¬°í
  • ±¸°­Ã»°áÁ¦
  • ½ºÇÁ·¹ÀÌ

Á¦8Àå ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Ä¡°úÀÇ¿ø
  • º´¿ø

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦12Àå °æÀï »óȲ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • 3M Company
  • Apotex Inc.
  • Blairex Laboratories Inc
  • Blistex Inc.
  • Bristol-Myers Squibb Company
  • Church & Dwight, Inc.
  • Colgate-Palmolive Company
  • Dr. Reddy's Laboratories Ltd
  • EPIEN Medical Inc.
  • GlaxoSmithKline PLC
  • Guilin Sanjin Pharmaceutical Co Ltd
  • ICPA Health Products Ltd.
  • Intas Pharmaceuticals Ltd.
  • LloydsPharmacy Limited
  • Meta Tubex Private Limited
  • Patterson Dental Supply, Inc.
  • Pfizer Inc.
  • Prince Care Pharma Private Limited
  • Raptakos Brett & Company Limited
  • Reckitt Benckiser Group PLC
  • Sinclair Pharma Ltd.
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd
  • Sunstar Suisse S.A
  • Taro Pharmaceutical Industries Ltd.
ksm 24.11.28

The Mouth Ulcers Treatment Market was valued at USD 1.23 billion in 2023, expected to reach USD 1.30 billion in 2024, and is projected to grow at a CAGR of 5.26%, to USD 1.77 billion by 2030.

The scope of the mouth ulcers treatment market encompasses the products and therapies aimed at alleviating the symptoms and promoting healing of mouth ulcers, or aphthous ulcers, which are painful sores that occur in the oral cavity. The necessity for these treatments arises from the prevalence of mouth ulcers, which affect a significant portion of the population due to causes like stress, nutritional deficiencies, and certain health conditions. Applications of mouth ulcer treatments include over-the-counter gels, creams, rinses, and prescribed medications, targeting immediate relief and accelerated healing. End-use segments involve hospitals, dental clinics, and home care settings, reflecting a broad consumer base from professional dental care to self-care solutions. Key growth factors driving the market include increasing awareness about oral health, advancements in pharmaceutical formulations, and the rising demand for quick-relief solutions. Emerging opportunities lie in the development of natural or herbal-based treatments, reflecting growing consumer preference for organic products. Furthermore, increasing urbanization and lifestyle changes are encouraging preventive care focus, presenting opportunities for companies to innovate preventive care solutions. However, market growth is challenged by factors like product efficacy concerns, potential side effects, and pricing pressures in emerging markets. Additionally, the lack of awareness in developing regions acts as a constraint. Innovations are seen in nanotechnology applications for sustained drug release and the use of biotechnology for targeted therapies. Greater integration of artificial intelligence in research for predictive modeling and personalized treatment plans represents a frontier for business growth. Research focused on minimizing side-effects and maximizing drug delivery efficacy is poised to improve treatment outcomes. The market remains competitive with established pharmaceutical companies and new entrants exploring bio-friendly and cost-effective solutions, emphasizing the importance of strategic alliances and continuous innovation to maintain market presence and leverage new opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 1.23 billion
Estimated Year [2024] USD 1.30 billion
Forecast Year [2030] USD 1.77 billion
CAGR (%) 5.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Mouth Ulcers Treatment Market

The Mouth Ulcers Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of mouth ulcers among global population
    • Availability of over-the-counter products for mouth ulcer treatment
    • Growing emphasis on patient-centric care mouth ulcer treatment plans
  • Market Restraints
    • Limited efficacy of existing treatments for mouth ulcers
  • Market Opportunities
    • Introduction of new and more effective mouth ulcer treatments
    • Rising healthcare expenditure and increased focus on oral health
  • Market Challenges
    • Certain side effects associated with mouth ulcers

Porter's Five Forces: A Strategic Tool for Navigating the Mouth Ulcers Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Mouth Ulcers Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Mouth Ulcers Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Mouth Ulcers Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Mouth Ulcers Treatment Market

A detailed market share analysis in the Mouth Ulcers Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Mouth Ulcers Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Mouth Ulcers Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Mouth Ulcers Treatment Market

A strategic analysis of the Mouth Ulcers Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Mouth Ulcers Treatment Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Apotex Inc., Blairex Laboratories Inc, Blistex Inc., Bristol-Myers Squibb Company, Church & Dwight, Inc., Colgate- Palmolive Company, Dr. Reddy's Laboratories Ltd, EPIEN Medical Inc., GlaxoSmithKline PLC, Guilin Sanjin Pharmaceutical Co Ltd, ICPA Health Products Ltd., Intas Pharmaceuticals Ltd., LloydsPharmacy Limited, Meta Tubex Private Limited, Patterson Dental Supply, Inc., Pfizer Inc., Prince Care Pharma Private Limited, Raptakos Brett & Company Limited, Reckitt Benckiser Group PLC, Sinclair Pharma Ltd., STADA Arzneimittel AG, Sun Pharmaceutical Industries Ltd, Sunstar Suisse S.A, and Taro Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Mouth Ulcers Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Analgesics, Antihistamine, Antimicrobial, and Corticosteroids.
  • Based on Formulation, market is studied across Gels & Ointments, Mouthwash, and Sprays.
  • Based on End-User, market is studied across Dental Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of mouth ulcers among global population
      • 5.1.1.2. Availability of over-the-counter products for mouth ulcer treatment
      • 5.1.1.3. Growing emphasis on patient-centric care mouth ulcer treatment plans
    • 5.1.2. Restraints
      • 5.1.2.1. Limited efficacy of existing treatments for mouth ulcers
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new and more effective mouth ulcer treatments
      • 5.1.3.2. Rising healthcare expenditure and increased focus on oral health
    • 5.1.4. Challenges
      • 5.1.4.1. Certain side effects associated with mouth ulcers
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Mouth Ulcers Treatment Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Analgesics
  • 6.3. Antihistamine
  • 6.4. Antimicrobial
  • 6.5. Corticosteroids

7. Mouth Ulcers Treatment Market, by Formulation

  • 7.1. Introduction
  • 7.2. Gels & Ointments
  • 7.3. Mouthwash
  • 7.4. Sprays

8. Mouth Ulcers Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Dental Clinics
  • 8.3. Hospitals

9. Americas Mouth Ulcers Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Mouth Ulcers Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Mouth Ulcers Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. Apotex Inc.
  • 3. Blairex Laboratories Inc
  • 4. Blistex Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. Church & Dwight, Inc.
  • 7. Colgate- Palmolive Company
  • 8. Dr. Reddy's Laboratories Ltd
  • 9. EPIEN Medical Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Guilin Sanjin Pharmaceutical Co Ltd
  • 12. ICPA Health Products Ltd.
  • 13. Intas Pharmaceuticals Ltd.
  • 14. LloydsPharmacy Limited
  • 15. Meta Tubex Private Limited
  • 16. Patterson Dental Supply, Inc.
  • 17. Pfizer Inc.
  • 18. Prince Care Pharma Private Limited
  • 19. Raptakos Brett & Company Limited
  • 20. Reckitt Benckiser Group PLC
  • 21. Sinclair Pharma Ltd.
  • 22. STADA Arzneimittel AG
  • 23. Sun Pharmaceutical Industries Ltd
  • 24. Sunstar Suisse S.A
  • 25. Taro Pharmaceutical Industries Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦